Although the results of 10 observational studies comparing CABG and drug-eluting stent (DES) implantation have been mostofthesestudieshadshortfollow-upperiods (12 to 24 months). In a meta-analysis of 24268 patients with multivessel CAD treated with CABG or DES,80 the incidences of death and MI were similar for the 2 procedures, but the frequency with which repeat revascularization was performed was roughly 4 times higher after DES implantation. Only 1 large RCT comparing CABG and DES implantation has been Table 2. Recommendation for Chelation Therapy 2012 Recommendation 2014 Focused Update Recommendation Comment Class III: No Benefit Class IIb Chelation therapy is not recommended with the intent of improving symptoms or reducing cardiovascular risk in patients with SIHD.38 41 (Level of Evidence: C) The usefulness of chelation therapy is uncertain for reducing cardiovascular events in patients with SIHD.38 42 (Level of Evidence: B) Modified recommendation (changed Class of Recommen - dation from III: No Benefit to IIb and Level of Evidence from C to B). SIHD indicates stable ischemic heart disease. Table 3. Recommendation for EECP 2012 Recommendation 2014 Focused Update Recommendation Comment Class IIb Class IIb EECP may be considered for relief of refractory angina in patients with SIHD.47 (Level of Evidence: B) EECP may be considered for relief of refractory angina in patients with SIHD.47 (Level of Evidence: B) 2012 recommendation remains current. EECP indicates enhanced external counterpulsation and SIHD, stable ischemic heart disease. Fihn et al 2014 Stable Ischemic Heart Disease Focused Update 1757 published. 